Plain-English translation of NCT06942039 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage study testing a new treatment approach for very young children (under 6 years old) who have been diagnosed with aggressive embryonal brain tumors. The study combines standard intensive chemotherapy with a newer medication called topotecan that is injected directly into the spine, followed by ongoing maintenance chemotherapy. Researchers want to see if this combination can work safely and effectively in this age group.
Aggressive brain tumors in very young children are serious and hard to treat. Doctors want to find better ways to fight these tumors while minimizing long-term side effects, since these children have many years of life ahead. This trial explores whether adding the new spinal medication can improve outcomes beyond current standard treatments.
You likely qualify if…
You likely don't qualify if…
Your child would receive three cycles of intensive chemotherapy given intravenously (into the vein), with the new medication topotecan injected into the spine during these early cycles. Next comes three more cycles of consolidation chemotherapy paired with stem cell rescue (where stem cells collected earlier are returned to the body). After that, your child would receive maintenance chemotherapy at home for about 48 to 54 weeks, with monthly spinal injections of the medication. You would return to the clinic every 3 months for 2 years after treatment ends to check for any signs of the tumor returning.
AI-generated summary from trial data · Aug 5, 2026 · Not medical advice
Canada